Decoding Kidney Disease: Can Genes Predict Treatment Success?
"New research explores how specific genes influence treatment response in children with nephrotic syndrome, offering hope for personalized medicine."
Nephrotic syndrome (NS) is a common kidney disorder in children, where the kidneys leak protein into the urine. While most children initially respond well to steroid treatment, many experience relapses or become resistant to steroids altogether. This can lead to long-term kidney damage and the need for more aggressive treatments. The big question is: why do some children respond to standard treatment while others don't?
Researchers have been exploring the role of genetics in predicting treatment outcomes for NS. One area of focus is the MDR1 gene, which is involved in how the body processes and eliminates certain drugs, including steroids. Variations in this gene, called polymorphisms, could affect how well steroids work in treating NS.
A recent study investigated the link between MDR1 gene polymorphisms and treatment response in Slovak children with NS. The goal was to see if specific genetic variations could predict whether a child would respond to prednisone, a common steroid medication used to treat NS. This article breaks down the study's findings and what they might mean for the future of personalized medicine in treating childhood kidney disease.
A Significant Kidney Health Burden
Kidney disease can affect health through progressive loss of kidney function and complications related to abnormal protein handling. Its impact varies by cause, disease severity, and response to treatment. Genetic information may eventually help clarify these differences, but it should be viewed as one part of a broader clinical assessment.
Current Clinical Assessment
Standard evaluation generally combines symptoms, laboratory testing, imaging, and, when appropriate, kidney biopsy. Treatment decisions are shaped by the suspected cause and the patient's clinical response. These approaches are useful but may not fully predict which individual will benefit from a particular therapy.
From Description to Structured Study
Descriptions of nephrotic syndrome reach back to physicians associated with Hippocrates, while Richard Bright described the triad of generalized edema, proteinuria, and kidney disease in 1827. Müller introduced the term “nephrosis” in 1905 for non-inflammatory kidney diseases. After the development of renal biopsy and steroid treatment, the International Study of Kidney Disease in Children (ISKDC) was established in 1965 with participants from North America, Europe, and Asia, creating an important framework for studying childhood nephrotic syndrome. (Reference URL 1 and Reference URL 2)
How do Genes Impact Steroid Treatment in Kidney Disease?
The study, published in Medical Science Monitor, analyzed the MDR1 gene in 46 children with NS and 100 healthy children. The researchers looked at three specific polymorphisms (1236T>C, 2677T>G, and 3435T>C) and how they related to treatment response, demographic factors, and pathological characteristics.
- 3435TC Genotype: Children with the 3435TC genotype had a significantly higher chance of responding to prednisone treatment.
- MDR1 1236CC and 2677GG: Children under 6 with NS had lower frequencies of MDR1 1236CC and 2677GG genotypes.
- Histology Matters: Children with minimal change disease (MCD) responded better to initial treatment compared to those with focal segmental glomerulosclerosis (FSGS).
New Biological Perspectives
Recent reviews describe nephrotic syndrome as involving excessive proteinuria, hypoalbuminemia, edema, and hyperlipidemia. The reported proteinuria threshold in one review is greater than 3–3.5 g per 24 hours, or a spot urine protein-to-creatinine ratio above 300–350 mg/mmol. Research also links nephrotic syndrome with complications including progressive kidney dysfunction, while proteinuria may accompany cellular or fibrous crescents and the development of rapidly progressive glomerulonephritis or focal glomerulosclerosis. (Reference URL 1 and Reference URL 2)
Limits of Prediction
Genetic prediction is unlikely to replace clinical judgment because kidney disease can arise through multiple pathways and patients may respond differently to the same treatment. A genetic result may clarify risk without guaranteeing treatment success. Any predictive model therefore needs careful validation before it is used to guide individual care.
Nephrotic and Nephritic Patterns
Nephrotic and nephritic syndromes describe different clinical patterns rather than interchangeable diagnoses. The nephritic syndrome is characterized by inflammation of the glomeruli, hematuria, variable proteinuria, hypertension, and reduced kidney function. Comparative clinical guides emphasize differences in causes, symptoms, laboratory findings, diagnosis, and treatment, making pattern recognition important when evaluating kidney disease. (Reference URL 1 and Reference URL 2)
Personalized Medicine for Kidney Disease: What's Next?
This study is an important first step in understanding how genetics can play a role in treating childhood NS. However, the researchers emphasize that larger, multi-center studies are needed to confirm these findings and explore how they apply to different ethnic groups. It's also important to remember that this is just one piece of the puzzle.
Outcomes Depend on More Than Genes
Real-world outcomes vary across nephrotic syndrome subtypes and patient characteristics. In older patients with primary nephrotic syndrome, baseline glomerular filtration rate and membranous or mesangiocapillary lesions were associated with higher risk of end-stage kidney disease, and 29% did not achieve even partial remission within six months of biopsy. A 2025 study reported poor kidney outcomes in genetic nephrotic syndrome, while outcomes in focal segmental glomerulosclerosis were strongly associated with proteinuria levels and patients with minimal change disease had better outcomes at each proteinuria level. (Reference URL 1 and Reference URL 2)
Forecasting a Changing Field
Market and epidemiology reports are projecting continued attention to nephrotic syndrome through 2035. The Nephrotic Syndrome Epidemiology Forecast 2026–2035 describes projected trends across eight major markets, including prevalence and other epidemiological measures. Other reports point to rising disease awareness, advancing pipeline therapies, and a shift toward targeted treatments, although these projections describe expected direction rather than guaranteed clinical outcomes. (Reference URL 1 and Reference URL 2)
Local Disease, Systemic Consequences
Nephrotic syndrome may be primary, meaning kidney-specific, or secondary to a broader systemic illness. It can involve severe swelling, foamy urine, weight gain from fluid retention, fatigue, and loss of appetite. Progressive kidney dysfunction and complications such as acute kidney injury illustrate why management must address both the kidney lesion and the patient's wider health needs. (Reference URL 1 and Reference URL 2)
Individual Experiences Matter
For people living with kidney disease, uncertainty about diagnosis, prognosis, and treatment response can make care difficult to navigate. Symptoms and outcomes may differ substantially between individuals, even when they share a clinical label. Genetic testing may add useful context, but its value depends on how clearly the result can inform a patient's actual treatment decisions.
While genetic testing isn't yet a standard part of NS treatment, this research suggests that it could be in the future. By identifying children who are less likely to respond to steroids, doctors could explore alternative treatments earlier, potentially preventing long-term kidney damage.
Ultimately, the goal is to move towards a more personalized approach to treating NS, where treatment decisions are tailored to each child's individual characteristics, including their genetic makeup, age, and the specific type of kidney disease they have.